Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344177 | 0.88 | — | — | |
| SCHEMBL21960463 | 0.88 | — | — | |
| SCHEMBL21948711 | 0.88 | — | — | |
| SCHEMBL25875129 | 0.80 | — | — | |
| SCHEMBL18754131 | 0.80 | — | — | |
| SCHEMBL17379374 | 0.76 | — | — | |
| SCHEMBL17379369 | 0.74 | KMT2A (0.32) | — | |
| SCHEMBL8275624 | 0.74 | CTSS (0.31) | — | |
| SCHEMBL14671049 | 0.74 | — | — | |
| SCHEMBL17379407 | 0.73 | KMT2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643417-B2 | Tetrahydrobenzofurodiazepinone compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-11643417-B2 | Tetrahydrobenzofurodiazepinone compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643417-B2 | Tetrahydrobenzofurodiazepinone compound and pharmaceutical use thereof | PIM1, PIM2, PIM3 | MMP13 4459/4885MMP1 2643/4885MMP2 3508/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | MMP13 1263/4885MMP1 2860/4885MMP2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.